BioVie Presents Protocol Design Of Upcoming SUNRISE-PD Phase 2 Trial Of Bezisterim In Patients With Early Parkinson's Disease At ATMRD 2024

6/25/24 8:11:51 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BIVI alert in real time by email

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa

Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson's disease that helped inform SUNRISE-PD trial design

CARSON CITY, Nev., June 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from two presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) held June 21-25, 2024 in Washington, D.C.

Get the next $BIVI alert in real time by email

Date	Price Target	Rating	Analyst
7/22/2022	$7.00	Overweight	Cantor Fitzgerald
11/30/2021	$50.00 → $27.00	Buy	B. Riley Securities

BioVie Presents Protocol Design Of Upcoming SUNRISE-PD Phase 2 Trial Of Bezisterim In Patients With Early Parkinson's Disease At ATMRD 2024

Chat with this insight

Recent Analyst Ratings for $BIVI

$BIVI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Do Cuong V bought 10,000 shares (SEC Form 4)

Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

$BIVI Market Insights

Live Market Insights

ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

BioVie Presents Protocol Design Of Upcoming SUNRISE-PD Phase 2 Trial Of Bezisterim In Patients With Early Parkinson's Disease At ATMRD 2024

12 Health Care Stocks Moving In Monday's After-Market Session

$BIVI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

B. Riley Securities reiterated coverage on BioVie with a new price target

$BIVI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BIVI Leadership Updates

Live Leadership Updates

$BIVI Press Releases

Fastest customizable press release news feed in the world

$BIVI Large Ownership Changes

This live feed shows all institutional transactions in real time.

Chief Medical Officer Palumbo Joseph M covered exercise/tax liability with 33,952 shares and was granted 116,000 shares, increasing direct ownership by 221% to 119,196 units (SEC Form 4)

Chief Financial Officer Kim Joanne Wendy covered exercise/tax liability with 23,202 shares and was granted 73,000 shares, increasing direct ownership by 113% to 93,940 units (SEC Form 4)

President & CEO Do Cuong V covered exercise/tax liability with 4,953 shares, covered exercise/tax liability with 46,953 shares and was granted 168,000 shares (SEC Form 4)

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

BioVie Announces the Appointment of a New Chief Medical Officer

BioVie Acquires Biopharma Assets from Privately Held NeurMedix

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded

BioVie Inc. Announces Closing of Registered Direct Offering

SEC Form SC 13G filed by BioVie Inc.

Amendment: SEC Form SC 13D/A filed by BioVie Inc.

SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

$BIVI SEC Filings

SEC Form 10-Q filed by BioVie Inc.

BioVie Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

BioVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$BIVI Financials

Live finance-specific insights

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Recent Analyst Ratings for
$BIVI

$BIVI
Insider Purchases

$BIVI
Market Insights

$BIVI
Analyst Ratings

$BIVI
Insider Trading

$BIVI
Leadership Updates

$BIVI
Press Releases

$BIVI
Large Ownership Changes

$BIVI
SEC Filings

$BIVI
Financials